Jack O’Mahony, a veteran with more than 40 years of experience in senior management positions in the global medical device industry, has joined the Global Orthopaedic Technology (Global) Board of Directors. Global’s Chief Executive Officer Andrew Fox-Smith, said “We are delighted that Jack has agreed to join our Board of Directors. Jack brings a wealth of experience in the international orthopaedic industry and possesses a deep understanding of sales, marketing and product distribution across global markets.”
O’Mahony Joins Global Orthopaedic Board
1 min read Premium comments
Founded in 1999, Global Orthopaedic Technology has grown to become Australia’s largest Australian-owned orthopedic implant designer and manufacturer, with two research, design and manufacturing facilities in Bella Vista and Seven Hills, in Sydney.
O’Mahony previously served as president of Synthes Asia Pacific; president and CEO of Cochlear; group president of Stryker International; vice president and CEO of Howmedica Orthopaedics and president of the Howmedica Division of Pfizer Medical Technology Group.
He said: “This is an exciting time for Global, with its recent acquisition by the Riverside Company, a new management team and a clear goal of increasing the sales of its existing range of orthopaedic implants and developing and commercializing new products across expanding markets. I am thrilled to be to be joining Global’s Board of Directors. I look forward to working with the new management team as part of the Riverside Company and supporting Global in meeting their business objectives.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.